Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Advances in Diagnosis, Risk Stratification, and Personalized Management in Acute...
share announcement

Advances in Diagnosis, Risk Stratification, and Personalized Management in Acute Coronary Syndromes

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 1524

Special Issue Editors

Dr. Efstratios Karagiannidis

E-Mail Website
Guest Editor
1. Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece
2. Department of Emergency Medicine, AHEPA University Hospital, 54636 Thessaloniki, Greece
Interests: myocardial infarction; heart failure; coronary artery disease; atrial fibrillation; arrhythmias
Special Issues, Collections and Topics in MDPI journals
Dr. Barbara P. Fyntanidou

E-Mail Website
Guest Editor
Department of Emergency Medicine, AHEPA University Hospital, 54636 Thessaloniki, Greece
Interests: thyroid surgery; hypocalcemia; laryngeal nerve; meta-analysis; hiv; infectious disease; pain; neuropathy
Dr. Aikaterini Apostolopoulou

E-Mail
Guest Editor
Department of Emergency Medicine, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
Interests: emergency medicine; gestational diabetes; cardiovascular disease; diet; pregnancy

Special Issue Information

Dear Colleagues,

Cardiovascular disease (CVD) remains the leading cause of death worldwide, with acute coronary syndromes (ACSs) contributing significantly to this high mortality. In recent years, we have witnessed remarkable advancements in our understanding of ACS, from the unraveling of foundational mechanisms and clinical pathophysiology to the discovery of biomarkers that refine diagnosis and treatment. These developments have notably enhanced patient care and outcomes.

However, despite state-of-the-art management, significant residual risk persists, highlighting the need for continued innovations in ACS care. This Special Issue will gather cutting-edge research on prevention, timely diagnosis, risk assessment, and treatment strategies in ACS.

We welcome submissions addressing, but not limited to, the following topics:

  • Novel diagnostic technologies and detection tools;
  • Improved risk stratification methods, scores, and indices;
  • Advances in clinical decision-making and personalized treatment approaches integrating genetics, biomarkers, and clinical data;
  • Strategies for residual risk reduction and evaluations of long-term patient outcomes.

By showcasing these advancements, this Special Issue will provide invaluable insights for researchers and clinicians striving to enhance ACS prognosis and patient quality of life.

We look forward to reading your contributions.

Dr. Efstratios Karagiannidis
Dr. Barbara P. Fyntanidou
Dr. Aikaterini Apostolopoulou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute coronary syndrome (ACS)
  • cardiovascular disease (CVD)
  • ischemic heart disease
  • emergency medicine
  • risk stratification
  • personalized treatment
  • antiplatelets
  • primary and secondary prevention

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 521 KiB  
Article
Culprit-Lesion Drug-Coated-Balloon Percutaneous Coronary Intervention in Patients Presenting with ST-Elevation Myocardial Infarction (STEMI)
by Jorge Sanz-Sánchez, Andrea Teira Calderón, David Neves, Carlos Cortés Villar, Antonela Lukic, Eva Rumiz González, Guillermo Sánchez-Elvira, Lino Patricio, José Luis Díez-Gil, Héctor M. García-García, Luis Martínez Dolz, J. Alberto San Román and Ignacio Amat Santos
J. Clin. Med. 2025, 14(3), 869; https://doi.org/10.3390/jcm14030869 - 28 Jan 2025
Viewed by 1325
Abstract
Background/Objectives: Drug-eluting stents (DESs) remain the standard of treatment for patients with ST-elevation myocardial infarction (STEMI). However, complications such as stent thrombosis and in-stent restenosis still pose significant risks. Drug-coated balloons (DCBs) have emerged as a promising alternative, but data for this [...] Read more.
Background/Objectives: Drug-eluting stents (DESs) remain the standard of treatment for patients with ST-elevation myocardial infarction (STEMI). However, complications such as stent thrombosis and in-stent restenosis still pose significant risks. Drug-coated balloons (DCBs) have emerged as a promising alternative, but data for this clinical scenario are still scarce. The objective was to evaluate the safety and efficacy of DCB culprit-lesion primary percutaneous coronary intervention (pPCI) in patients presenting with STEMI and to evaluate its impact on the microcirculatory territory. Methods: An observational retrospective study was conducted across six European centers. Results: In total, 118 patients were included. Of these, 82.2% were male, with a median age of 67 years (IQR 36–92); 28% patients presented with stent thrombosis and most of them (94%) underwent paclitaxel-DCB-pPCI. The median follow-up was 23.2 months (IQR 6.7–77.3). Target lesion failure (TLF) rates were low (3.4%), with no differences between patients presenting with native coronary vessel and stent thrombosis (4.7% vs. 0%; p = 0.205). Overall mortality rates at follow-up were 7%, with only 1.8% attributed to cardiac causes. A target lesion revascularization (TLR) rate of 1.8% was observed, with no target vessel myocardial infarction reported. A subgroup of patients (42; 35.6%) underwent an adenosine-free angiographic microvascular resistance (AMR) analysis. The median AMR was 4.7 (3.9–5.5) and was greater in the stent thrombosis group than in the native coronary group (5.1 vs. 4.6; p = 0.038) with no clinical differences between patients based on the AMR. Conclusions: DCB-pPCI has emerged as an alternative potential treatment for patients presenting with STEMI, with few long-term adverse cardiac events. Despite the encouraging outcomes, these findings underscore the need for a large randomized clinical trial powered by a relevant clinical outcome in order to elucidate the role of DCB-PCI in patients presenting with STEMI. Full article
(This article belongs to the Special Issue Advances in Diagnosis, Risk Stratification, and Personalized Management in Acute Coronary Syndromes)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop